Phynova Obtains FDA Approval Of Its IND To Enter Into A Clinical Trial Of PYN17 For The Treatment Of Chronic Hepatitis C

Phynova Group PLC (AIM: PYN), a developer of pharmaceuticals derived from Chinese botanical drugs targeting viral and metabolic diseases and cancer, is pleased to announce the introduction of its first drug candidate into clinical trials in the US.